Physical Stimulation Activates Stem Cells to Regenerate Damaged Nerves
New research shows mechano-electrical stimulation can trigger stem cells to repair peripheral nerve damage completely.
20 articles
New research shows mechano-electrical stimulation can trigger stem cells to repair peripheral nerve damage completely.
New biomaterial conduits and stem cell treatments show promise for repairing damaged peripheral nerves and restoring lost function.
Researchers used AI screening to identify bavisant, a histamine receptor drug, as a potential therapy to repair nerve damage in MS.
Engineered zinc finger therapy reduced pain-sensing gene activity by 50% in primates for 6 months without major side effects.
A terminated multicenter RCT examined whether mechanical cough assistance plus NIV could cut re-intubation rates in ICU patients with weak cough.
A miniaturized PEMF device failed to raise SpO2 in healthy rats, suggesting COVID-19 benefits may be disease-specific.
A flexible PEMF coil patch delivers targeted electromagnetic stimulation to skin wounds, offering a tunable, non-invasive approach to chronic wound repair.
Enhanced stem cells reduced inflammation and improved bladder function in rats with nerve damage.
A biodegradable microneedle stent achieves sutureless intestinal anastomosis while releasing anti-inflammatory drugs triggered by local inflammation.
Revolutionary cell therapy and tissue engineering approaches could transform treatment for nerve injuries affecting millions worldwide.
Novel biomaterial treatment simultaneously prevents nerve degeneration and promotes regeneration, preserving visual function after optic nerve injury.
A Phase 1/2 trial tests four rounds of intrathecal MSC injections in ALS patients, targeting both safety and disease progression.
Small pilot study tests whether enriched fat transfers can reduce amputation site pain and improve prosthetic use.
Revolutionary nanoneedle technology creates molecular replicas of living brain tissue, enabling repeated monitoring of glioma progression and treatment response.
A phase 1 dose-escalation trial tests the safety of AAV-delivered ND4 gene therapy in patients with Leber's hereditary optic neuropathy.
Breakthrough technology allows precise activation of genes in living animals using electromagnetic fields, opening new therapeutic possibilities.
A Phase 1/2 trial of NFS-02 gene therapy for LHON-associated vision loss was terminated before completion, raising questions about mitochondrial gene therapy.
MSC-derived exosomes delivered via ear injection protect vestibular hair cells, cut apoptosis, and boost autophagy better than dexamethasone.
Researchers developed biological pacemaker cells from stem cells that successfully restored heart rhythm in animal studies.
Temperature-controlled plasma offers precise, minimally invasive treatment for laryngocele removal with improved surgical outcomes.